These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 18788687)

  • 1. A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria.
    Suankratay C; Jutivorakool K; Jirajariyavej S
    J Med Assoc Thai; 2008 Aug; 91(8):1172-81. PubMed ID: 18788687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone.
    Lee S; Song DY; Cho SH; Kwon KT
    Microb Drug Resist; 2014 Feb; 20(1):39-44. PubMed ID: 23941639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors.
    Ozgunes I; Erben N; Kiremitci A; Kartal ED; Durmaz G; Colak H; Usluer G; Colak E
    Saudi Med J; 2006 May; 27(5):608-12. PubMed ID: 16680246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China.
    Hu B; Ye H; Xu Y; Ni Y; Hu Y; Yu Y; Huang Z; Ma L
    Curr Med Res Opin; 2010 Jun; 26(6):1443-9. PubMed ID: 20394469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis.
    Peco-Antić A; Paripović D; Buljugić S; Spasojević-Dimitrijeva B; Cvetković M; Laban-Nestorović S; Milosevski-Lomić G
    Srp Arh Celok Lek; 2012; 140(5-6):321-5. PubMed ID: 22826985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of the frog skin peptide, ascaphin-8 and its lysine-substituted analogs against clinical isolates of extended-spectrum beta-lactamase (ESBL) producing bacteria.
    Eley A; Ibrahim M; Kurdi SE; Conlon JM
    Peptides; 2008 Jan; 29(1):25-30. PubMed ID: 18068868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
    Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
    Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
    Wells WG; Woods GL; Jiang Q; Gesser RM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon.
    Kanafani ZA; Mehio-Sibai A; Araj GF; Kanaan M; Kanj SS
    Am J Infect Control; 2005 Aug; 33(6):326-32. PubMed ID: 16061138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy.
    Ozden E; Bostanci Y; Yakupoglu KY; Akdeniz E; Yilmaz AF; Tulek N; Sarikaya S
    Urology; 2009 Jul; 74(1):119-23. PubMed ID: 19464043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital.
    Koksal F; Ak K; Kucukbasmaci O; Samasti M
    Chemotherapy; 2009; 55(4):293-7. PubMed ID: 19521075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended spectrum â-lactamase producing multidrug resistant clinical bacterial isolates at National Public Health Laboratory, Nepal.
    Poudyal S; Bhatta DR; Shakya G; Upadhyaya B; Dumre SP; Buda G; Kandel BP
    Nepal Med Coll J; 2011 Mar; 13(1):34-8. PubMed ID: 21991699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam.
    Nicolle LE; Mulvey MR
    Scand J Infect Dis; 2007; 39(8):748-9. PubMed ID: 17654359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.